by Raynovich Rod | Jul 19, 2022 | 2024-25 Life Science Portfolios
Broad Market Rallies Despite Currency Headwinds Healthcare (XLV) was down 2.11% yesterday but stabilized today at $129 handle. MedTech (IHI) is up 2.8%. a must have sector in your healthcare portfolio. Small Cap Biotech very strong with XBI up 4%. HealthCare and...
by Raynovich Rod | Jul 17, 2022 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-1 JY/21…Small Cap Rally Intact especially with Speculative Stocks Ok we got our nice small cap rally. Most of these stocks are somewhat isolated from macro and financials. But they need fresh news with pipeline updates. Mirati Therapeutics up over 15%...
by Raynovich Rod | Jul 11, 2022 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-3 JY 15 3:30p… Broad rally led by DOW up 1.91%. Healthcare rally XLV up 2%, led by vaccine stocks as variants like BA.5 infection case counts pick up. MRNA, BNTX, NVAX all up over 3%. Novavax (NVAX) vaccine approved yesterday . Boosters being urged....
by Raynovich Rod | Jul 5, 2022 | 2024-25 Life Science Portfolios
UPDATE-1 JY7 Biotech rally intact. The rally from the June 15 bottom and breakthrough technicals on June 23 is confirmed. Biotechs were so beaten down with valuations at cash levels. Our new picks among smaller cap biotechs have done well this week. We will summarize...
by Raynovich Rod | Jun 27, 2022 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-3 July 5 11a EDT Rally in speculative biotech stocks with XBI up1.85% to $77 handle. Early movers: AGEN, CRSP, CYRX, DNA, QDEL, ROIV, VCYT all on our focus list. Added to Moderna (MRNA) at $153. Market indices in red on recession fears with S%P 500 down 1.9%...
by Raynovich Rod | May 30, 2022 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks, Macro
Update-4 June 8 Sideways market with trading opportunities in Small cap biotechs. With markets so choppy day to day and volatile within day it is hard to trade. But in my most recent trades I am more hopeful with this buying window. The bellwether remains XBI which...
by Raynovich Rod | May 15, 2022 | 2025 Rayno Biopharmaceuticals Portfolio
May 25 -Update-3 ..We will take this little rally after all the turmoil recently. Our Strategy has not changed since January which is to stay with large cap biopharma stocks . We would like to pick some winners among the smaller cap biotech and diagnostics stocks but...
by Raynovich Rod | Apr 11, 2022 | 2025 Rayno Biopharmaceuticals Portfolio, Healthcare stocks
Update-2 4/13 11;36 AM EDT….GSK buys Sierra Oncology (SRRA) for $1.9B https://www.bizjournals.com/sanjose/news/2022/04/13/glaxosmithkline-to-buy-sierra-oncology-for-19b.html?ana=yahoo XBI up 2.48% to $89 handle, ARKG up 2.35%. Large caps lag except REGN up. ABBV...
by Raynovich Rod | Apr 4, 2022 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-2 …4/6 In volatile end of day trading with Tech stocks and the NASDAQ hit hard down 2.2%, healthcare stocks were winners with the XLV up 1.5%. Other sector winners were staples, energy, real estate and utilities. As one pundit put it, ” the FED is...
by Raynovich Rod | Mar 28, 2022 | 2024-25 Life Science Portfolios, Biopharmaceuticals
4/1/22 Blah market but biotech and healthcare holds.Rally at last 30 min. Spec small caps on a green screen with both ARKG and XBI up. We are trading these stocks off a bottom. IWM up 0.9% to $207 level. Gene therapy stocks rallying: CRSP, EDIT, NTLA. Large caps...
